The pharmaceutical company Roche Diabetes Care and the Hospital de la Fundación Private Asilo de Granollers, to which the General Hospital of this municipality belongs to the province of Barcelona, have signed their first Shared Risk Agreement to provide patients with diabetes with the continuous implantable glucose meter Eversense XL.
This agreement, facilitated by HiTT, a consulting firm specializing in the transfer of innovation to patients, will enable people with type I diabetes to use the latest technology to measure glucose for one year. "This type of agreement favors the adoption of innovative technologies that aim to improve the quality of life of patients and accompany them in their daily lives," says Roche Diabetes Spain manager Lisa Huse.
The director general of the General Hospital of Granollers, Dr. Rafael Lledó, adds that "thanks to this agreement, is available to these patients another glucose sensor different from those on the market to try to improve not only the control of diabetes." , but their quality of life ».
Through the signed contract, Roche Diabetes Care will provide the General Hospital of Granollers with the purchase of sensors and transmitters needed to meet patients' needs for 12 months. In this way, the center can offer innovative technology with guarantees of success, because if the use of the devices generate an extra cost, this laboratory will compensate it.
"Shared risk agreements are being shown as solutions for patients' access to new technologies in which all parties win: patients, healthcare providers and innovation developers," says HiTT CEO Oriol Solà-Morales .
Patients at the Granollers General Hospital who will have access to the use of the continuous implantable glucose sensor are people with type I diabetes who have controlled the disease with a continuous infusion of insulin for more than six months and who still have frequent hypoglycaemia. or asymptomatic.